The recent identification of a selective inhibitor of METTL3 catalytic activity that dramatically decreases tumor growth in mouse AML models suggests that m6A methylation by METTL3 could serve as a promising therapeutic target for cancer treatment (Yankova et al., 2021). This evidence concerns the gene METTL3 and acute myeloid leukemia.